| Name | Title | Contact Details |
|---|
uBiome is the leading microbial genomics company. We are pioneering a new era of microbiome-based precision medicine. We allow doctors, patients, and citizen scientists to learn about the human microbiome with unprecedented accuracy and speed.
Outbound AI is Conversation AI built for healthcare. Founded in 2021, the Seattle-based startup is breaking new ground with cloud technologies that serve as workforce multipliers to drive productivity while improving the daily job experience for human talent. The company`s inaugural offering includes a portfolio of intelligent Virtual Agents specially trained to streamline phone-based administrative work across the revenue cycle, including claims status, eligibility and benefits verification, prior authorization and more. Outbound AI is led by a passionate team of health and voice tech veterans and backed by several preeminent venture capital firms.
Edward Hospital & Health Services is a full-service, regional health care organization, offering access to a wide variety of complex medical specialties and innovative programming.
We are the global leader in hearing solutions and services for retail expertise, customization and consumer care. Almost 12,000 professionals every day in a network of 3,700 points of sale, 3,600 service centers and 1,750 affiliates, give back the joy of hearing, feeling and living to thousands of people across the world. Being the one and only global company in our industry focused purely on hearing care services, we are able to bring seven decades of experience to every single consultation. That means striving to give our customers a premium experience by equipping our people with the necessary time, the best and exclusive tools, the latest technology and the finest training from the moment they join.
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.